The global COVID-19 pandemic has created numerous challenges for persons with diabetes and for the health professionals who help manage their care. Higher rates of COVID-19 related hospitalizations and mortality, difficulty in accessing medicines and supplies, and the lack of in-person clinic visits due to lockdowns and social distancing and the resulting rapid shift to tele-medicine have caused an unprecedented overturning of the status quo. As the US healthcare system is forced to deal with disparities in care, can it benefit from procedures and low-cost technology that are standard in India? With the US ahead in the COVID-19 timeline, what are lessons that India can learn from the US experience? Will the future of diabetes care in India and the US look more similar than it has in the past?